FDA endorses Novavax's pivotal trial design for flu vaccine; Forty Seven bags funding for myelodysplastic syndromes program
→ Following a stream of setbacks with its RSV vaccine, Novavax is touting some regulatory progress of another candidate for a change. The FDA has apparently green-lighted the Phase III trial design for NanoFlu, its adjuvanted, recombinant quadrivalent flu vaccine targeting the elderly (65 or older). The trial is expected to begin in a couple of months and generate top-line data in the first quarter of 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.